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Abstract 
We report the case of a 68-year-old immunocompetent patient with a dilatation of the as-
cending aorta, intraluminal vegetations, and pseudoaneurysmatic bulging who presented with 
unilateral fungal endogenous endophthalmitis 8 days after coronary angiogram. The isolated 
pathogen resulted to be Magnusiomyces capitatus, a filamentous, yeast-like fungus that can 
be commonly found in normal human microflora, with an immunosuppression-related patho-
genicity. A literature research revealed a single case of ophthalmic infection – a keratitis – 
caused by this pathogen. Furthermore, we add a review of mycotic endophthalmitis related to 
aortic infection. © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Fungal endogenous endophthalmitis is a severe ocular disease associated with potentially 
poor visual outcomes, derived from hematogenous propagation of a mycotic agent into the 
eye. Affected patients usually have predisposing systemic conditions, such as immunosup-
pression (iatrogenic, diabetes mellitus, malignancy, or HIV) indwelling catheters, intravenous 
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drug use, or recent major surgical procedures. However, this condition occasionally occurs 
also in healthy, immunocompetent patients. The most commonly involved pathogen is the 
yeast Candida albicans, followed by molds such as Aspergillus fumigatus [1]. In detail, almost 
half of the patients with endophthalmitis caused by Aspergillus species have a condition of 
iatrogenic immunosuppression and organ transplantation and require a more aggressive 
therapy, while C. albicans-related endophthalmitis has a more indolent course, and patients 
usually present with a better visual acuity (VA) [2]. Generally, the diagnosis is clinical, and 
many patients have positive fungal cultures from extraocular sites; therefore, intraocular cul-
tures are not mandatory for each patient. If the diagnosis is unclear, confirmatory laboratory 
testing, such as cultures or polymerase chain reaction from vitreous tap, can be performed. 
Treatment is usually represented by systemic antifungals and intravitreal antifungal injec-
tions, alone or in combination with pars plana vitrectomy (PPV) [3]. 
Case Presentation 
We report the case of an immunocompetent 68-year-old patient who was admitted to the 
emergency department due to angina. He had undergone coronary artery bypass graft opera-
tion for obstructive coronaropathy 4 years earlier. Coronary angiogram was urgently per-
formed and revealed an enlargement of the ascending aorta with intraluminal thrombus-like 
material partially ulcerating the aortic wall, associated with severe stenosis of the coronary 
arteries. The patient was hospitalized since ascending aorta replacement and multiple coro-
nary arteries bypass graft was indicated. After 8 days, while waiting for surgery, he started 
complaining of redness and blurred vision in the right eye (RE). The ophthalmological past 
medical history was unremarkable. VA was 20/125 in the RE and 20/20 in the left eye. On 
clinical examination of the RE, he presented conjunctival injection, posterior synechiae, Tyn-
dall 2+, no hypopion, and faint anterior chamber cells 1+. He was phakic with a moderate cat-
aract (2+) (Fig. 1a). Severe vitritis with 4+ haze was also present. Despite the severe vitreous 
inflammation and poor pupil dilatation, at fundus biomicroscopy, a rounded, circumscribed, 
white-yellowish retinal lesion, slightly greater than 1 disc diameter in size, was found in the 
temporal mid-periphery of the retina (Fig. 1c). At optical coherence tomography (OCT), the 
lesion appeared as a preretinal, round-shaped hyperreflective lesion with a homogeneous in-
ternal pattern, laying on the retinal surface; the retinal layers underneath the lesion were not 
clearly visible due to a posterior shadowing effect (Fig. 1d). Ultrasound examination showed 
inflammatory signs in the vitreous chamber, represented by multiple moderately reflective 
mobile dot echoes, and a preretinal lesion with intermediate echogenicity in the transverse B-
scan of the temporal retina (Fig. 1b). Ocular features were clinically consistent with fungal 
endophthalmitis. The left eye was normal. Broad-spectrum antimycotic therapy with voricon-
azole, both intravenous (6 mg/kg every 12 h for 24 h, then 4 mg/kg every 12 h for 7 days) and 
intravitreal (100 µg/0.1 mL), was immediately started, with subsequent modest visual im-
provement to 20/100 in the RE. A vitreous tap was also performed at the time of intravitreal 
therapy. 
After 2 days, the patient became hemodynamically unstable, thus requiring urgent car-
diac surgery intervention. What seemed to be an intra-aneurysmal thrombus during coronary 
angiography revealed to be an intraluminal mycotic vegetation. Microbiological examinations 
disclosed colonies of Magnusiomyces capitatus, sensible to liposomal amphotericin B. In addi-
tion, the vitreous tap resulted positive for the same pathogen. Therefore, endovenous therapy 
with liposomal amphotericin B was started at the dosage of 3 mg/kg daily. 
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This confirmed the initial clinical diagnosis of endogenous endophthalmitis in the RE, 
with the source of primary mycotic infection at the level of the aortic wall. Three weeks after 
cardiac surgery, although no signs of worsening were disclosed, ocular examination did not 
show any improvement despite the therapy administered. VA in RE was stable at 20/100. 
Therefore, 30 days after the initial systemic and intravitreal therapy with voriconazole, a more 
aggressive approach was decided, and the patient underwent 27-gauge three-port PPV and 
phacoemulsification with intraocular lens implantation associated with an intravitreal injec-
tion of amphotericin B (5 µg/0.1 mL) under peribulbar anesthesia. After the initial core vitrec-
tomy, the infective lesion became clearly visible and was removed using both forceps and the 
vitreous cutter. During surgery, an additional small focus was disclosed at the posterior pole 
(Fig. 2a). Endolaser was performed over the area where the larger infective focus was located. 
The RE VA progressively improved up to 20/25 two weeks after ocular surgery. On examina-
tion, the anterior and the vitreous chambers were clear, and there was no evidence of recur-
rence of retinal infiltrate (Fig. 2b–e). Eight months after surgery, VA is maintained at 20/25 
without evidence of any signs of inflammation. 
Discussion 
We report a case of endogenous endophthalmitis in an immunocompetent patient caused 
by the pathogen M. capitatus (formerly Geotrichum capitatum), a filamentous yeast-like fun-
gus colonizing human skin and the mucosa of the respiratory and digestive tracts, which pro-
duces rapidly proliferating, flat, white colonies with acute-angled hyphae and abundant co-
nidia formation [4]. 
A literature search revealed a single case of ocular infection caused by this pathogen, a 
keratomycosis in a patient affected by sarcoidosis who had previously undergone corneal 
transplantation for a postinfectious corneal scar 5 years before. However, no signs of vitreous 
inflammation and endophthalmitis were noted. The patient was treated with topical, intra-
cameral and systemic voriconazole, followed by corneal transplantation. The cultures of the 
aqueous were positive for M. capitatus [5]. 
An additional search focused on endophthalmitis associated with mycotic aortic aneu-
rysm highlighted 2 cases. The first was a case of Aspergillus endophthalmitis occurring 14 days 
after percutaneous coronary intervention in a patient affected by pseudoaneurysmatic dilata-
tion of the ascending aorta. The patient presented with reduced VA and vitreous flare and 
underwent PPV associated with an intravitreal injection of amphotericin B. The authors were 
not able to provide data on postsurgical visual and anatomic outcomes since the patient had a 
prolonged course complicated by intracerebral bleeding and respiratory failure and died on 
postoperative day 39 [6]. The second case was an immunocompetent patient who had under-
gone bioprosthetic aortic valve replacement three months earlier with a pseudoaneurysm of 
the ascending and mid-descending aorta caused by Aspergillus, spreading to the eye and caus-
ing endophthalmitis. He was treated with systemic antimycotic therapy (amphotericin-B, 
voriconazole). However, the prognosis was unfavorable, and the patient died after a pro-
longed hospital course [7]. 
Since our patient was immunocompetent, we hypothesize that the primary event was a 
clinically silent mycotic infection of the ascending aorta, mimicking an aneurysm that then 
spread to the RE, causing endogenous endophthalmitis. 
Current recommendations for the treatment of endogenous fungal endophthalmitis are 
different according to the precise etiology. More specifically, for Candida endophthalmitis, the 
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best treatment appears to be PPV associated with intravitreal injection of amphotericin or 
voriconazole and systemic antifungal therapy, which has to be maintained for either at least 6 
weeks or until the resolution of ocular involvement. Immunocompromised patients need the 
same treatment. However, in the case that they cannot tolerate surgery, intravitreal injection 
with voriconazole and amphotericin should be performed at baseline and repeated as needed. 
Voriconazole is also used to treat infections resistant to fluconazole and amphotericin B. It is 
also indicated against Paecilomyces and Fusarium species. Guidelines for the treatment of As-
pergillus endophthalmitis recommend amphotericin B, both intravenously and intravitreally, 
potentially associated with PPV in sight-threatening cases; as an alternative, either systemic 
or intravitreal voriconazole may be used [8]. It cannot be excluded that the seeding of the in-
fection was promoted by the insertion of the coronary angiography catheter in the ascending 
aorta where the mycotic material was located. We decided to treat our patient initially with 
intravitreal and systemic voriconazole, since we preferred not to perform vitrectomy until he-
modynamic stability was reached. After cardiac surgery had been performed, PPV was con-
sidered viable. It must be noted that, after obtaining the microbiological results on the infec-
tious material, antifungal therapy was shifted from voriconazole to liposomal amphotericin B, 
to which the pathogen resulted sensitive. 
To our knowledge, this is the first reported case of endogenous endophthalmitis caused 
by M. capitatus. 
The case is unusual not only for the clinical presentation – mycotic endophthalmitis in an 
immunocompetent patient, caused by an uncommon pathogen – but also for the primary site 
of infection and the mechanism of fungal spread. Our case and the others described above 
were all managed with medical and surgical therapy, with favorable visual and anatomical 
outcomes in our case.  
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Fig. 1. Preoperative clinical presentation. a Color photographs of the anterior segment of the RE; posterior 
synechiae and pigment deposits on anterior crystalloid are evident. b Ten-MHz B-scan ocular ultrasound 
of the RE clearly documents retinal lesion and vitreous flare. c Color fundus photography of the posterior 
pole. d Horizontal OCT scan through the large infective focus shows a well-defined, hyper-reflective retinal 
lesion protruding into the vitreous cavity. 
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Fig. 2. a Intraoperative fundus photography: posterior pole and mid-periphery of the RE. Fungal infiltrate 
is visible temporally to the macula, and a smaller infiltrate can be appreciated inferotemporal to the mac-
ula. b–e Postoperative status at the 1-month follow-up. Postoperative color photographs of the anterior 
segment (b) and fundus (c) show a clear and quiet anterior segment and absence of retinal lesions. OCT 
scans reveal focal atrophy in the area where the larger infective focus was located (d) and the presence of 
an epiretinal membrane that does not alter the retinal thickness and profile of the macula (e). 
 
